Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Case report: Pregnancy

Von Willebrand syndrome and anti-phospholipid syndrome

    • Cases
    • Education
    • Gynecology
    • Hematology
    • RX
  • 2 minute read

A patient with anti-phospholipid syndrome undergoes fertility treatment because she had already suffered two miscarriages. During a laboratory examination at the beginning of pregnancy, Von Willebrand syndrome is also diagnosed. However, treating both conditions simultaneously is challenging.

* VEYVONDI® may be used only when therapy with desmopressin (DDAVP) alone is ineffective or contraindicated. Dosage and frequency must be determined on an individual basis depending on clinical judgment and based on patient weight, type and severity of bleeding episodes/surgical intervention, and based on monitoring of appropriate clinical and laboratory measurements. See also current technical information VEYVONDI® www.swissmedicinfo.ch

Comment by Rosa Sonja Alesci, MD

Von Willebrand syndrome and anti-phospholipid syndrome often occur together. This is difficult in that the two conditions require contrasting treatments. Thus, anti-phospholipid syndrome is treated with heparin and ASA. However, ASA should be avoided in the presence of Von Willebrand syndrome. The situation is particularly difficult in pregnant women, as anti-phospholipid syndrome can lead to abortions and Von Willebrand syndrome to bleeding if left untreated. In the present case, therefore, the anti-phospholipid syndrome was initially treated with heparin alone and recombinant Von Willebrand factor (Veyvondi®) was administered simultaneously to minimize the patient’s bleeding. Due to the difficult situation, very frequent monitoring of the patient was necessary during this time in order to be able to react quickly and adjust the treatment if necessary. After six courses of treatment with Veyvondi® , the laboratory values had stabilized to such an extent that therapy for Von Willebrand syndrome could be stopped. Heparin treatment is currently continued and supplemented with ASA to further control the anti-phospholipid syndrome.

Abbreviations

AK = antibody; aPTT = activated partial thromboplastin time; FVIII:C = factor VIII activity; Ig = immunoglobulin; PFA-100 = Platelet Function Analyzer 100; VWF:Ag = von Willebrand factor antigen; VWF:CBA = von Willebrand factor collagen binding activity; VWF:RCo = von Willebrand factor ristocetin cofactor activity.

 

 

C-APROM/CH//0761   05/2020

 

VEYVONDI ® Brief technical information


Z: 
Active ingredient: Vonicogum alfa. 
I: 
Treatment of bleeding or surgery-related hemorrhage in the of–Willebrand–disease when therapy with desmopressin (DDAVP) alone is ineffective or contraindicated. 
D: 
Dosage and frequency must be individualized based on clinical judgment and based on patient weight, type and severity of bleeding episodes/surgical intervention, and based on monitoring of appropriate clinical and laboratory measurements; Intravenous administration. AI: Hypersensitivity to the active substance or any of the excipients. Known allergic reaction to mouse– or hamster proteins. 
VM: 
There are hypersensitivity– or allergic reactions occurred, which may progress to severe anaphylaxis. Monitor patients closely during infusion. Neutralizing antibodies can be formed against Von–Willebrand–Develop factor. There is a risk of thrombotic events. 
SS: 
Use only when clearly indicated. 
UW: 
From–Willebrand–Factor Inhibitors, Hypersensitivity– or allergic reactions, tremor, hypertension, vertigo, deep vein thrombosis, ECG changes. 
IA: 
There are no known interactions. P: Lyophilisate with 650 I.U. or 1,300 I.U. with 5 ml (resp. 10 ml for 1,300 I.E.) water for injection. Levy category B. Z: Takeda Pharma AG, 8152 Opfikon. You can find detailed information at www.swissmedicinfo.ch

Partner
  • takeda_neu_4
Autoren
  • Dr. med. Rosa Sonja Alesci
Related Topics
  • veyvondi
  • Willebrand syndrome.
Previous Article
  • Dizziness in old age

Peripherally or centrally determined?

  • Education
  • General Internal Medicine
  • Geriatrics
  • Neurology
  • ORL
  • RX
View Post
Next Article
  • Cardiovascular diseases

When the skin beats on the heart

  • Cardiology
  • Dermatology and venereology
  • Education
  • Rheumatology
  • RX
View Post
You May Also Like
View Post
  • 4 min
  • Case Report

Mycosis fungoides in an 11-year-old child

    • Allergology and clinical immunology
    • Cases
    • Dermatology and venereology
    • Education
    • Oncology
    • Pediatrics
    • RX
    • Studies
View Post
  • 6 min
  • EHA 2025

Progress in multiple myeloma

    • Congress Reports
    • Hematology
    • Oncology
    • RX
    • Studies
View Post
  • 6 min
  • Interstitial lung diseases

Artificial intelligence improves ILD diagnosis

    • Education
    • General Internal Medicine
    • Pneumology
    • Prevention and health care
    • RX
    • Studies
View Post
  • 7 min
  • Management of patients after alloHCST

ERS/EBMT guideline recommendations on pulmonary cGvHD

    • Education
    • General Internal Medicine
    • Genetics
    • Hematology
    • Pneumology
    • RX
    • Studies
View Post
  • 3 min
  • Pyoderma gangraenosum

New study data confirm the validity of the PARACELSUS score

    • Congress Reports
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Geriatrics
    • Orthopedics
    • Prevention and health care
    • RX
    • Studies
    • Surgery
View Post
  • 8 min
  • Progressive multiple sclerosis

New horizons: from BTK inhibitors to remyelination

    • Education
    • Genetics
    • Neurology
    • RX
    • Studies
View Post
  • 6 min
  • Cutaneous and especially facial metastases

Rare manifestations of esophageal carcinoma

    • Cases
    • Dermatology and venereology
    • Education
    • Gastroenterology and Hepatology
    • Oncology
    • RX
    • Surgery
View Post
  • 7 min
  • Rare pulmonary syndromes

Yellow nail and Swyer-James syndrome

    • CME continuing education
    • Dermatology and venereology
    • General Internal Medicine
    • Infectiology
    • Pneumology
    • RX
Top Partner Content
  • Herpes zoster

    Zum Thema
Top CME content
  • 1
    Colorectal cancer screening – an update
  • 2
    Yellow nail and Swyer-James syndrome
  • 3
    Individual therapy management for an optimized outcome – an update
  • 4
    Doing sport without fear or risk
  • 5
    UV protection and skin cancer screening – Update 2025

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.